Accumulation of clots causes some of the most severe symptoms of sickle cell disease, including strokes, kidney failure, ...

There are around 17,500 people with sickle cell disease ... best care to patients fast,” said Nice chief executive Dr Samantha Roberts. Ludovic Fenaux, senior vice president at Vertex ...

Gallbladder issues are a frequent but manageable complication of sickle cell disease. Awareness of the symptoms and risk factors, combined with regular medical care, can help patients address ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem cell transplant ...

It is believed around 1,700 people could be eligible for the treatment, while the NHS estimates around 50 people a year will ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...